Inhibition of survivin reduces HIF-1α, TGFβ1 and TFE3 in salivary adenoid cystic carcinoma

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Wang, Yu Fan ^a   Ma, Si Rui ^a   Wang, Wei Ming ^a   Huang, Cong Fa ^a   Zhao, Zhi Li ^a   Liu, Bing ^a   Zhang, Wen Feng ^a   Zhao, Yi Fang ^a   Zhang, Lu ^a   Sun, Zhi Jun ^a  

^a Wuhan University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; GLUCOSE TRANSPORTER 1; HEMATOXYLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF APOPTOSIS PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; NAPHTHOQUINONE; SEPANTRONIUM BROMIDE; TFE3 PROTEIN, HUMAN;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENVIRONMENTAL STRESS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MYOEPITHELIUM CELL; PLEOMORPHIC ADENOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SALIVARY GLAND CARCINOMA; SCORING SYSTEM; TISSUE MICROARRAY; TRANSCRIPTION INITIATION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CASE CONTROL STUDY; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SALIVARY GLAND TUMOR; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, ADENOID CYSTIC; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CLUSTER ANALYSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; NAPHTHOQUINONES; NEOPLASM GRADING; SALIVARY GLAND NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84915785657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114051     Document Type: Article

References (51)

1. Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, et al. (2012) Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer 118: 4444-4451.
2. Vekony H, Ylstra B, Wilting SM, Meijer GA, van de Wiel MA, et al. (2007) DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res 13: 3133-3139.
3. Persson M, Andren Y, Mark J, Horlings HM, Persson F, et al. (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106: 18740-18744.
4. Barnes LE, Reichart JW, Reichart P, Sidransky D (2005) World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC Press: Lyon. pp. 221-281.
5. Lamers F, Schild L, Koster J, Versteeg R, Caron HN, et al. (2012) Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 48: 763-771.
6. Dresang LR, Guastafierro A, Arora R, Normolle D, Chang Y, et al. (2013) Response of merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor. PLoS One 8: e80543.
7. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, et al. (2003) Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626.
8. Ko YH, Roh SY, Won HS, Jeon EK, Hong SH, et al. (2010) Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol 2: 30.
9. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22: 1682-1688.
10. Pollard P, Wortham N, Barclay E, Alam A, Elia G, et al. (2005) Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 205: 41-49.
11. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3: 721-732.
12. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, et al. (2002) Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 196: 204-212.
13. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, et al. (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206: 291-304.
14. Costa AF, Tasso MG, Mariano FV, Soares AB, Chone CT, et al. (2012) Levels and patterns of expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation. Histopathology 60: 816-825.
15. Chen YQ, Zhao CL, Li W (2009) Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res 28: 29.
16. Kanwar JR, Kamalapuram SK, Kanwar RK (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 16: 485-494.
17. Hung SP, Yang MH, Tseng KF, Lee OK (2013) Hypoxia-induced secretion of TGF-beta1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant 22: 1869-1882.
18. Hanna C, Hubchak SC, Liang X, Rozen-Zvi B, Schumacker PT, et al. (2013) Hypoxia-inducible factor-2alpha and TGF-beta signaling interact to promote normoxic glomerular fibrogenesis. Am J Physiol Renal Physiol 305: F1323-1331.
19. Copple BL (2010) Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int 30: 669-682.
20. Song K, Shankar E, Yang J, Bane KL, Wahdan-Alaswad R, et al. (2013) Critical role of a survivin/TGF-beta/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells. PLoS One 8: e61896.
21. Poh YW, Gan SY, Tan EL (2012) Effects of IL-6, IL-10 and TGF-beta on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells. Exp Oncol 34: 85-89.
22. Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y (2005) The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res 24: 415-421.
23. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, et al. (2004) Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100: 751-757.
24. Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, et al. (2006) Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 9: 473-484.
25. Thavaraj S, Paterson IC, Hague A, Prime SS (2005) Over-expression of TGF-beta1 in Smad4-deficient human oral carcinoma cells causes tumour regression in vivo by mechanisms that sensitize cells to apoptosis. J Pathol 205: 14-20.
26. Hua X, Liu X, Ansari DO, Lodish HF (1998) Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 12: 3084-3095.
27. Tang YL, Fan YL, Jiang J, Li KD, Zheng M, et al. (2014) C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget 5: 1491-1501.
28. Wang L, Wang Y, Bian H, Pu Y, Guo C (2013) Molecular characteristics of homologous salivary adenoid cystic carcinoma cell lines with different lung metastasis ability. Oncol Rep 30: 207-212.
29. Ge XY, Yang LQ, Jiang Y, Yang WW, Fu J, et al. (2014) Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. PLoS One 9: e101207.
30. Wang YF, Zhang W, He KF, Liu B, Zhang L, et al. (2014) Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma. Apoptosis 19: 748-758.
31. Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, et al. (2012) Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 18: 5304-5313.
32. Sun ZJ, Zhang L, Zhang W, Hall B, Bian Y, et al. (2013) Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model. PLoS One 8: e74888.
33. Huang CF, Zhang L, Ma SR, Zhao ZL, Wang WM, et al. (2013) Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma. PLoS One 8: e83479.
34. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, et al. (2012) Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31: 3322-3332.
35. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248.
36. Altieri DC (2013) Targeting survivin in cancer. Cancer Lett 332: 225-228.
37. Arlt A, Muerkoster SS, Schafer H (2013) Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 332: 346-358.
38. Mulay K, Puthyapurayil FM, Mohammad JA, Hasnat Ali M, Honavar SG, et al. (2013) Adenoid cystic carcinoma of the lacrimal gland: role of nuclear survivin (BIRC5) as a prognostic marker. Histopathology 62: 840-846.
39. Liao Y, Zeng H, Wang X, Huang Y, Chen N, et al. (2009) Expression patterns and prognostic significance of inhibitor of apoptosis proteins in adenoid cystic carcinoma and pleomorphic adenoma of lachrymal gland. Exp Eye Res 88: 4-11.
40. Haq R, Fisher DE (2010) Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 29: 3474-3482.
41. Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, et al. (2011) Interdependence of HIF-1alpha and TGF-beta/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 300: F898-905.
42. Zhang L, Sun ZJ, Bian Y, Kulkarni AB (2013) MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Lett 331: 230-238.
43. Bian Y, Terse A, Du J, Hall B, Molinolo A, et al. (2009) Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res 69: 5918-5926.
44. Dong L, Ge XY, Wang YX, Yang LQ, Li SL, et al. (2013) Transforming growth factor-beta and epithelialmesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 49: 1051-1058.
45. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021.
46. Ko YH, Lee MA, Hong YS, Lee KS, Jung CK, et al. (2007) Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. Jpn J Clin Oncol 37: 805-811.
47. Jia J, Zhang W, Liu JY, Chen G, Liu H, et al. (2012) Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PLoS One 7: e51549.
48. Sun ZJ, Chen G, Zhang W, Hu X, Huang CF, et al. (2010) Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase. J Pharmacol Exp Ther 334: 500-512.
49. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG (2011) Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 12: 815-824.
50. Helbig L, Koi L, Bruchner K, Gurtner K, Hess-Stumpp H, et al. (2014) Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys 88: 159-166.
51. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.